Evidence map›Paper›PMID 41424740›Full record

ArticleOncoTargets and therapy2025

Clinical Significance of MYBL2 Expression in Hepatocellular Carcinoma: Impact on Overall Survival.

Chia-Chi Chen, Ching-Ting Wei, Chin-Feng Hsuan, Teng-Hung Yu, Wei-Chin Hung, Cheng-Ching Wu, Thung-Lip Lee, Wei-Hua Tang, Fu-Mei Chung, Yau-Jiunn Lee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chia-Chi ChenDepartment of Pathology, E-Da Hospital, I-Shou University, Kaohsiung, 82445, Taiwan.ORCID 0000-0002-4905-3408
Ching-Ting WeiDivision of General Surgery, Department of Surgery, E-Da Hospital, I-Shou University, Kaohsiung, 82445, Taiwan.
Chin-Feng HsuanSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, 82445, Taiwan.
Teng-Hung YuSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, 82445, Taiwan.
Wei-Chin HungSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, 82445, Taiwan.
Cheng-Ching WuSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, 82445, Taiwan.
Thung-Lip LeeDivision of Cardiology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, 82445, Taiwan.
Wei-Hua TangDivision of Cardiology, Department of Internal Medicine, Ministry of Health and Welfare Yuli Hospital, Hualien, 98142, Taiwan.
Fu-Mei ChungDivision of Cardiology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, 82445, Taiwan.
Yau-Jiunn LeeLee's Endocrinologic Clinic, Pingtung, 90000, Taiwan.
Chia-Chang HsuThe School of Chinese Medicine for Post Baccalaureate, College of Medicine, I-Shou University, Kaohsiung, 82445, Taiwan.ORCID 0000-0001-6620-8013

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Transcription factor MYB proto-oncogene like 2 (MYBL2) is involved in cell cycle regulation and proliferation, and it has been implicated in various cancers. However, its expression pattern and clinical significance in hepatocellular carcinoma (HCC) are unclear. Therefore, the aim of this study was to evaluate the tissue expression of MYBL2 in patients with HCC and evaluate associations with clinicopathological factors and prognosis. Patients and Methods: We enrolled 88 patients with HCC who underwent hepatectomy from October 2023 to January 2025 and analyzed MYBL2 expressions in non-tumorous and tumorous tissue samples using immunohistochemistry. The patients were then categorized into high and low expression groups, and clinicopathological factors were compared. Cox proportional hazard regression and Kaplan-Meier survival analyses were used to explore the prognostic significance of MYBL2 expression. Results: MYBL2 immunohistochemistry score was significantly associated with survival (p for trend = 0.038). Kaplan-Meier analysis demonstrated that those with a high MYBL2 expression were associated with lower overall survival compared to those with a low MYBL2 expression (p = 0.029). An independent association was found between high MYBL2 expression in tumorous tissues and poor overall survival (p = 0.047). However, multivariate analysis indicated that MYBL2 expression was not an independent risk factor for overall survival. Conclusion: The results indicated an association between MYBL2 and HCC prognosis, suggesting that it could be used as a prognostic biomarker and potentially be a therapeutic target. Further research is required to clarify the molecular mechanisms by which MYBL2 drives tumor progression and to explore its potential in targeted therapy for HCC.

Indexed as

hepatocellular carcinomaimmunohistochemistryMYBL2overall survival

Identifiers

PMID41424740
PMCPMC12717811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.